{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:54:09Z","timestamp":1770749649492,"version":"3.50.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04322-8","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:40:17Z","timestamp":1750149617000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced detection of primary aldosteronism in hypertensive patients with obstructive sleep apnea using a novel diagnostic algorithm"],"prefix":"10.1007","volume":"90","author":[{"given":"Shruti N.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyla","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insoo","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandana","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"4322_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1515\/cclm-2017-0217","volume":"56","author":"SM Dick","year":"2018","unstructured":"S.M. Dick, M. Queiroz, B.L. Bernardi, A. Dall\u2019Agnol, L.A. Brondani, S.P. Silveiro, Update in diagnosis and management of primary aldosteronism. Clin. Chem. Lab. Med 56, 360\u2013372 (2018). https:\/\/doi.org\/10.1515\/cclm-2017-0217.","journal-title":"Clin. Chem. Lab. Med"},{"key":"4322_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.7326\/0003-4819-66-6-1079","volume":"66","author":"NM Kaplan","year":"1967","unstructured":"N.M. Kaplan, Hypokalemia in the hypertensive patient. Ann. Intern. Med. 66, 1079\u20131090 (1967). https:\/\/doi.org\/10.7326\/0003-4819-66-6-1079.","journal-title":"Ann. Intern. Med."},{"key":"4322_CR3","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/162804","volume":"2011","author":"RM Fagugli","year":"2011","unstructured":"R.M. Fagugli, C. Taglioni, Changes in the perceived epidemiology of primary hyperaldosteronism. Int. J. Hypertens. 2011, 162804 (2011). https:\/\/doi.org\/10.4061\/2011\/162804.","journal-title":"Int. J. Hypertens."},{"key":"4322_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.7326\/M17-2237","volume":"167","author":"EV Adlin","year":"2017","unstructured":"E.V. Adlin, Subclinical primary aldosteronism. Ann. Intern. Med. 167, 673\u2013674 (2017). https:\/\/doi.org\/10.7326\/M17-2237.","journal-title":"Ann. Intern. Med."},{"key":"4322_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ando.2016.01.006","volume":"77","author":"J-P Baguet","year":"2016","unstructured":"J.-P. Baguet, O. Steichen, C. Mounier-V\u00e9hier, P. Gosse, SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 1: epidemiology of PA, who should be screened for sporadic PA?. Ann. Endocrinol. 77, 187\u2013191 (2016). https:\/\/doi.org\/10.1016\/j.ando.2016.01.006.","journal-title":"Ann. Endocrinol."},{"key":"4322_CR6","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1161\/STROKEAHA.120.033990","volume":"52","author":"J McCarthy","year":"2021","unstructured":"J. McCarthy, J. Yang, B. Clissold, M.J. Young, P.J. Fuller, T. Phan, Hypertension management in stroke prevention. Stroke 52, e626\u2013e634 (2021). https:\/\/doi.org\/10.1161\/STROKEAHA.120.033990.","journal-title":"Stroke"},{"key":"4322_CR7","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"A.H. Ahmed, R.D. Gordon, N. Sukor, E. Pimenta, M. Stowasser, Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J. Clin. Endocrinol. Metab. 96, 2904\u20132911 (2011). https:\/\/doi.org\/10.1210\/jc.2011-0138.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4322_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.amjmed.2021.07.041","volume":"135","author":"PC Conroy","year":"2021","unstructured":"P.C. Conroy, S. Hernandez, C.E. Graves, K.C.-H. Menut, S. Pearlstein, C. Liu, W.T. Shen, J. Gosnell, J.A. Sosa, S. Roman, Q.-Y. Duh, I. Suh, Screening for primary aldosteronism is underutilized in patients with obstructive sleep apnea. Am. J. Med. 135, 60 (2021). https:\/\/doi.org\/10.1016\/j.amjmed.2021.07.041.","journal-title":"Am. J. Med."},{"key":"4322_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"W.F. Young, Primary aldosteronism: renaissance of a syndrome. Clin. Endocrinol. 66, 607\u2013618 (2007). https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02775.x.","journal-title":"Clin. Endocrinol."},{"key":"4322_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.mce.2003.10.006","volume":"217","author":"M Stowasser","year":"2004","unstructured":"M. Stowasser, R.D. Gordon, Primary aldosteronism\u2014careful investigation is essential and rewarding. Mol. Cell. Endocrinol. 217, 33\u201339 (2004). https:\/\/doi.org\/10.1016\/j.mce.2003.10.006.","journal-title":"Mol. Cell. Endocrinol."},{"key":"4322_CR11","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, M. Stowasser, W.F. Young Jr, The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4322_CR12","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","volume":"105","author":"A Vaidya","year":"2020","unstructured":"A. Vaidya, R.M. Carey, Evolution of the primary aldosteronism syndrome: updating the approach. J. Clin. Endocrinol. Metab. 105, 3771 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa606.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4322_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"AM Sawka","year":"2001","unstructured":"A.M. Sawka, W.F. Young, G.B. Thompson, C.S. Grant, D.R. Farley, C. Leibson, J.A. van Heerden, Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med. 135, 258\u2013261 (2001). https:\/\/doi.org\/10.7326\/0003-4819-135-4-200108210-00010.","journal-title":"Ann. Intern. Med."},{"key":"4322_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"G.P. Rossi, M. Cesari, C. Cuspidi, G. Maiolino, M.V. Cicala, V. Bisogni, F. Mantero, A.C. Pessina, Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62, 62\u201369 (2013). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01316.","journal-title":"Hypertension"},{"key":"4322_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2013","unstructured":"V. Fourkiotis, O. Vonend, S. Diederich, E. Fischer, K. Lang, S. Endres, F. Beuschlein, H.S. Willenberg, L.C. Rump, B. Allolio, M. Reincke, M. Quinkler, For the Mephisto Study Group, Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur. J. Endocrinol. 168, 75\u201381 (2013). https:\/\/doi.org\/10.1530\/EJE-12-0631.","journal-title":"Eur. J. Endocrinol."},{"key":"4322_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.surg.2022.05.041","volume":"173","author":"K Wright","year":"2023","unstructured":"K. Wright, M. Mahmoudi, N. Agrawal, H. Simpson, M.S. Lui, H.L. Pachter, K. Patel, J. Prescott, I. Suh, Implementation of a formal sleep center\u2013based screening protocol for primary aldosteronism in patients with obstructive sleep apnea. Surgery 173, 59\u201364 (2023). https:\/\/doi.org\/10.1016\/j.surg.2022.05.041.","journal-title":"Surgery"},{"key":"4322_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5664\/jcsm.27497","volume":"5","author":"LJ Epstein","year":"2009","unstructured":"L.J. Epstein, D. Kristo, P.J. Strollo, N. Friedman, A. Malhotra, S.P. Patil, K. Ramar, R. Rogers, R.J. Schwab, E.M. Weaver, M.D. Weinstein, Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J. Clin. Sleep. Med. 5, 263\u2013276 (2009).","journal-title":"J. Clin. Sleep. Med."},{"key":"4322_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41371-023-00875-1","volume":"38","author":"L Faconti","year":"2024","unstructured":"L. Faconti, S. Kulkarni, C. Delles, V. Kapil, P. Lewis, M. Glover, T.M. MacDonald, I.B. Wilkinson, Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the british and irish hypertension society. J. Hum. Hypertens. 38, 8\u201318 (2024). https:\/\/doi.org\/10.1038\/s41371-023-00875-1.","journal-title":"J. Hum. Hypertens."},{"key":"4322_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72, 658\u2013666 (2018). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11568.","journal-title":"Hypertension"},{"key":"4322_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6, 51\u201359 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30367-4.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4322_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","volume":"18","author":"AF Turcu","year":"2022","unstructured":"A.F. Turcu, J. Yang, A. Vaidya, Primary aldosteronism - a multidimensional syndrome. Nat. Rev. Endocrinol. 18, 665\u2013682 (2022). https:\/\/doi.org\/10.1038\/s41574-022-00730-2.","journal-title":"Nat. Rev. Endocrinol."},{"key":"4322_CR22","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","volume":"46","author":"HE K\u00fcnzel","year":"2012","unstructured":"H.E. K\u00fcnzel, K. Apostolopoulou, A. Pallauf, S. Gerum, K. Merkle, S. Schulz, E. Fischer, V. Brand, M. Bidlingmaier, S. Endres, F. Beuschlein, M. Reincke, Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J. Psychiatr. Res. 46, 1650\u20131654 (2012). https:\/\/doi.org\/10.1016\/j.jpsychires.2012.08.025.","journal-title":"J. Psychiatr. Res."},{"key":"4322_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"J.M. Brown, M. Siddiqui, D.A. Calhoun, R.M. Carey, P.N. Hopkins, G.H. Williams, A. Vaidya, The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann. Intern. Med. 173, 10 (2020). https:\/\/doi.org\/10.7326\/M20-0065.","journal-title":"Ann. Intern. Med."},{"key":"4322_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","volume":"69","author":"R Baudrand","year":"2017","unstructured":"R. Baudrand, F.J. Guarda, C. Fardella, G. Hundemer, J. Brown, G. Williams, A. Vaidya, Continuum of renin-independent aldosteronism in normotension. Hypertension 69, 950\u2013956 (2017). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08952.","journal-title":"Hypertension"},{"key":"4322_CR25","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1161\/HYPERTENSIONAHA.124.22884","volume":"81","author":"M Marcelli","year":"2024","unstructured":"M. Marcelli, C. Bi, J.W. Funder, M.J. McPhaul, Comparing ARR versus suppressed PRA as screening tests for primary aldosteronism. Hypertension 81, 2072\u20132081 (2024). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.22884.","journal-title":"Hypertension"},{"key":"4322_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.684111","volume":"12","author":"P J\u0119drusik","year":"2021","unstructured":"P. J\u0119drusik, B. Symonides, J. Lewandowski, Z. Gaciong, The effect of antihypertensive medications on testing for primary aldosteronism. Front. Pharm. 12, 684111 (2021). https:\/\/doi.org\/10.3389\/fphar.2021.684111.","journal-title":"Front. Pharm."},{"key":"4322_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/archinte.1972.03650060041007","volume":"130","author":"RM Carey","year":"1972","unstructured":"R.M. Carey, J.G. Douglas, J.R. Schweikert, G.W. Liddle, The syndrome of essential hypertension and suppressed plasma renin activity: normalization of blood pressure with spironolactone. Arch. Intern. Med. 130, 849\u2013854 (1972). https:\/\/doi.org\/10.1001\/archinte.1972.03650060041007.","journal-title":"Arch. Intern. Med."},{"key":"4322_CR28","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"B. Williams, T.M. MacDonald, S. Morant, D.J. Webb, P. Sever, G. McInnes, I. Ford, J.K. Cruickshank, M.J. Caulfield, J. Salsbury, I. Mackenzie, S. Padmanabhan, M.J. Brown, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015). https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","journal-title":"Lancet"},{"key":"4322_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"B. Williams, T.M. MacDonald, S.V. Morant, D.J. Webb, P. Sever, G.T. McInnes, I. Ford, J.K. Cruickshank, M.J. Caulfield, S. Padmanabhan, I.S. Mackenzie, J. Salsbury, M.J. Brown, K. Balakrishnan, T. Burton, J. Cannon, D. Collier, C. Coughlan, R. D\u2019Souza, E. Enobakhare, E. Findlay, C. Gardiner-Hill, P. Gupta, J. Helmy, C. Helmy, L. Hobbs, R. Hobbs, S. Hood, R. Iles, S. Kean, S. Kwok, P. Lacy, I. MacIntyre, J. Mackay, N. Markandu, U. Martin, L. McCallum, G. McCann, A. McGinnis, V. Melville, S. Muir, K.S. Myint, S. Nazir, J. Palmer, R. Papworth, K. Rutkowski, M. Saxena, A. Schumann, H. Soran, A. Stanley, S. Thom, A. Webb, C. White, R. Wilson, A. Zak, Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 6, 464\u2013475 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(18)30071-8.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4322_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.11909\/j.issn.1671-5411.2016.03.020","volume":"13","author":"Z-N Jin","year":"2016","unstructured":"Z.-N. Jin, Y.-X. Wei, Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J. Geriatr. Cardiol. 13, 333\u2013343 (2016). https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.03.020.","journal-title":"J. Geriatr. Cardiol."},{"key":"4322_CR31","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/HJH.0b013e3283492219","volume":"29","author":"JJ Sim","year":"2011","unstructured":"J.J. Sim, E.H. Yan, I.L.A. Liu, S.A. Rasgon, K. Kalantar-Zadeh, D.A. Calhoun, S.F. Derose, Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J. Hypertens. 29, 1553\u20131559 (2011). https:\/\/doi.org\/10.1097\/HJH.0b013e3283492219.","journal-title":"J. Hypertens."},{"key":"4322_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5603\/EP.2013.0019","volume":"64","author":"A Prejbisz","year":"2013","unstructured":"A. Prejbisz, E. Florczak, A. Klisiewicz, P. Dobrowolski, H. Janaszek-Sitkowska, P. Biele\u0144, E. Szwench-Pietrasz, E. Warcho\u0142-Celi\u0144ska, S. Ko\u0142odziejczyk-Kruk, J. Janas, M. Kabat, J. Imiela, P. Sliwi\u0144ski, A. Januszewicz, Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynol. Pol. 64, 363\u2013367 (2013). https:\/\/doi.org\/10.5603\/EP.2013.0019.","journal-title":"Endokrynol. Pol."},{"key":"4322_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1470320310366581","volume":"11","author":"A Di Murro","year":"2010","unstructured":"A. Di Murro, L. Petramala, D. Cotesta, L. Zinnamosca, E. Crescenzi, C. Marinelli, M. Saponara, C. Letizia, Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J. Renin Angiotensin Aldosterone Syst. 11, 165\u2013172 (2010). https:\/\/doi.org\/10.1177\/1470320310366581.","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"4322_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1378\/chest.125.1.112","volume":"125","author":"DA Calhoun","year":"2004","unstructured":"D.A. Calhoun, M.K. Nishizaka, M.A. Zaman, S.M. Harding, Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125, 112\u2013117 (2004). https:\/\/doi.org\/10.1378\/chest.125.1.112.","journal-title":"Chest"},{"key":"4322_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.5664\/jcsm.8960","volume":"17","author":"P Dobrowolski","year":"2021","unstructured":"P. Dobrowolski, S. Ko\u0142odziejczyk-Kruk, E. Warcho\u0142-Celi\u0144ska, M. Kabat, U. Ambroziak, A. Wr\u00f3bel, P. Piekarczyk, A. Ostrowska, M. Januszewicz, P. \u015aliwi\u0144ski, J.W.M. Lenders, A. Januszewicz, A. Prejbisz, Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. J. Clin. Sleep. Med. 17, 629\u2013637 (2021). https:\/\/doi.org\/10.5664\/jcsm.8960.","journal-title":"J. Clin. Sleep. Med."},{"key":"4322_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01638-w","volume":"24","author":"AMC Ong Lopez","year":"2024","unstructured":"A.M.C. Ong Lopez, L.E. Tiu, D.C. Dimayuga, O.A.C. Dampil, E.S. Mendoza, M.L. Villa, A.M. Macabuag-Oliva, Sparing confirmatory testing in primary aldosteronism (SCIPA): a multicenter retrospective diagnostic accuracy study. BMC Endocr. Disord. 24, 105 (2024). https:\/\/doi.org\/10.1186\/s12902-024-01638-w.","journal-title":"BMC Endocr. Disord."},{"key":"4322_CR37","doi-asserted-by":"publisher","first-page":"dgaa282","DOI":"10.1210\/clinem\/dgaa282","volume":"105","author":"K Wang","year":"2020","unstructured":"K. Wang, J. Hu, J. Yang, Y. Song, P.J. Fuller, H. Hashimura, W. He, Z. Feng, Q. Cheng, Z. Du, Z. Wang, L. Ma, S. Yang, Q. Li, Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism. J. Clin. Endocrinol. Metab. 105, dgaa282 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa282.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4322_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep32103","volume":"6","author":"V-C Wu","year":"2016","unstructured":"V.-C. Wu, S.-M. Wang, C.-H. Chang, Y.-H. Hu, L.-Y. Lin, Y.-H. Lin, S.-C.J. Chueh, L. Chen, K.-D. Wu, Long term outcome of aldosteronism after target treatments. Sci. Rep. 6, 32103 (2016). https:\/\/doi.org\/10.1038\/srep32103.","journal-title":"Sci. Rep."},{"key":"4322_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"M. Velema, T. Dekkers, A. Hermus, H. Timmers, J. Lenders, H. Groenewoud, L. Schultze Kool, J. Langenhuijsen, A. Prejbisz, G.-J. van der Wilt, J. Deinum, SPARTACUS investigators: quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J. Clin. Endocrinol. Metab. 103, 16\u201324 (2018). https:\/\/doi.org\/10.1210\/jc.2017-01442.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4322_CR40","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1097\/HJH.0000000000003513","volume":"41","author":"ME Woode","year":"2023","unstructured":"M.E. Woode, K. Wong, C.M. Reid, M. Stowasser, G. Russell, S. Gwini, M.J. Young, P.J. Fuller, J. Yang, G. Chen, Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis. J. Hypertens. 41, 1615\u20131625 (2023). https:\/\/doi.org\/10.1097\/HJH.0000000000003513.","journal-title":"J. Hypertens."},{"key":"4322_CR41","unstructured":"N.C. Industrial Commission, CPT codes and fees: pathology and laboratory, Accessed Data and Year: May 31, 2025 (2015). https:\/\/www.ic.nc.gov\/ncic\/pages\/80000.htm."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04322-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04322-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04322-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:51Z","timestamp":1758772851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04322-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4322"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04322-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"I.S. is an advisory board member at Corcept Therapeutics. N.A. is an advisory board member at Xeris, Amryt, and Camurus and has received research support from Amryt, Recordati, and Ascendis. The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}